Ascletis Begins U.S. Phase I Trials of Monthly Obesity Drugs
Hong Kong, China, August 10, 2026 Ascletis Pharma Inc. has announced the initiation of two Phase I clinical studies...
ASC36
Advertisement
Ribo Unveils Positive Phase 2a Data for Vortosiran in CAD
SHANGHAI, China and MÖLNDAL, Sweden, July 22, 2026 Suzhou Ribo Life Science Co., Ltd. and its subsidiary Ribocure Pharmaceuticals...
Ascletis Reports Superior ASC36_35 Weight Loss Data at EASD 2026
HONG KONG, July 23, 2026 Ascletis Pharma Inc. has announced that new preclinical data for its investigational obesity therapy...
InnoCare Doses First Patient in ICP-B208 ADC Clinical Trial
BEIJING, China, July 6, 2026 InnoCare Pharma has announced a significant milestone in its oncology pipeline with the first...
Ascletis Submits FDA INDs for Next-Generation Obesity Drugs
HONG KONG, July 6, 2026 Ascletis Pharma Inc. has announced the submission of two Investigational New Drug (IND) applications...
Advertisement
